Athena Athena

X
[{"orgOrder":0,"company":"Lucy Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lucy Therapeutics Debuts Novel Therapeutic Agents for Parkinson\u2019s Disease at Michael J. Fox Foundation Annual Conference","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical"}]

Find Clinical Drug Pipeline Developments & Deals by Lucy Therapeutics

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            LucyTx-1209 and LucyTx-1212 are designed to target one of the functions of the protein complex F1F0-ATPase, which acts within the ETC. The Lucy Therapeutics compounds reduced levels of α-synuclein, which accumulate and are a pathological hallmark of PD.

            Lead Product(s): LucyTx-1209

            Therapeutic Area: Neurology Product Name: LucyTx-1209

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 13, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY